根据名称进行药物检索

Nortriptyline Oral Solution 与 Zoloft

Nortriptyline Oral Solution 与 Zoloft互相作用以及同时服用的可能性。

检测结果:

Nortriptyline Oral Solution <> Zoloft

现实性: 07.09.2022 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

前服用郁症，告诉医生，如果你还用舍曲林。你可能需要的剂量调整或特别的测试，以便安全地把这两种药物在一起。这种组合可以增加的影响郁症在你的身体。你应该通知你的医生如果你有症状的镇静剂、口干、视力模糊便秘、或尿潴留。你可能还具有改变的意识、混乱、贫穷肌肉的协调、腹部痉挛、颤抖、瞳孔扩张、出汗、高血压和高心率。重要的是，你告诉你的医疗保健提供者有关的所有其他药物的使用，包括维生素和草药。不停止使用药物而不首先说你的医生第一次。

医界专家:

密切监测:共同给予与舍曲林，可能增加等离子体浓度的一些三环抗抑郁药(机师). 拟议的机制是舍曲林抑制CYP450 2D6，同工酶负责的新陈代谢的间隙很多的抗抑郁和精神药物。中等至大幅度增加(达到250%)在血浆水平已经报告了对地昔帕明和郁症. Pharmacodynamically，结合舍曲林(或任何其他选择性的血清素再吸收抑制剂)和TCA可能会加强风险的血清素综合症，这是一个罕见的，但是严重的和潜在的致命状况的思想导致过度刺激的脑干5HT1A受体。该综合症已经报告了在一个情况涉及舍曲林和阿米替林.

管理：谨慎建议，如果舍曲林(或其他Ssri)规定，有机师. 药物反应和等离子体TCA级别应监测更密切地随时舍曲林加入或撤离治疗的患者中稳定在他们现有的抗抑郁治疗方案，并TCA剂量调整是必要的。患者应密切监测为的迹象和症状的TCA毒性(例如，镇静、口干、视力模糊便秘、尿潴留)和/或过量的血清素的活动(例如，中枢神经系统烦躁不安，改变意识、混乱、肌阵挛、共济失调、腹部痉挛、次高烧、颤抖、瞳孔扩张、发汗解表、高血压、心动过速).

来源

Sternbach H "The serotonin syndrome." Am J Psychiatry 148 (1991): 705-13
Corkeron MA "Serotonin syndrome - a potentially fatal complication of antidepressant therapy." Med J Aust 163 (1995): 481-2
Barros J, Asnis G "An interaction of sertraline and desipramine." Am J Psychiatry 150 (1993): 1751
Popli AP, Baldessarini RJ, Cole JO "Interactions of serotonin reuptake inhibitors with tricyclic antidepressants." Arch Gen Psychiatry 51 (1994): 666-7
Ereshefsky L, Riesemman C, Lam YW "Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6." Clin Pharmacokinet 29(Suppl 1) (1995): 10-8; discussion 18-9
Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ "The effect of sertraline on the pharmacokinetics of desipramine and imipramine." Clin Pharmacol Ther 62 (1997): 145-56
Riesenman C "Antidepressant drug interactions and the cytochrome p450 system: a critical appraisal." Pharmacotherapy 15 (1995): s84-99
Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6
Taylor D "Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination - interactions and therapeutic uses." Br J Psychiatry 167 (1995): 575-80
von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI "Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo." J Pharmacol Exp Ther 268 (1994): 1278-83
Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S "Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine." J Clin Psychopharmacol 14 (1994): 90-8
Mathew NT, Tietjen GE, Lucker C "Serotonin syndrome complicating migraine pharmacotherapy." Cephalalgia 16 (1996): 323-7
Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE "The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes." Br J Clin Pharmacol 34 (1992): 262-5
Alderman CP, Lee PC "Serotonin syndrome associated with combined sertraline-amitriptyline treatment." Ann Pharmacother 30 (1996): 1499-500
Mills KC "Serotonin syndrome: A clinical update." Crit Care Clin 13 (1997): 763
Lydiard RB, Anton RF, Cunningham T "Interactions between sertraline and tricyclic antidepressants." Am J Psychiatry 150 (1993): 1125-6
Fischer P "Serotonin syndrome in the elderly after antidepressive monotherapy." J Clin Psychopharmacol 15 (1995): 440-2